

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C 1, Block G,
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051.

Company Symbol: **QMSMEDI**

ISIN: INEOFMW01018

Sub: Press Release - QMS Medical Allied Services Screens 2 Lakhs Patients through 25,000

Unique Service Programs

Pursuant to Regulation 30 of the SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, enclosed herewith the copy of the Press Release which will be given with regard to the QMS Medical Allied Services Screens 2 Lakhs Patients through 25,000 Unique Service Programs.

A copy of the press release will also be uploaded on the Company's website.

Kindly take the same on your records and oblige.

Thanking you,

Yours truly,

FOR QMS MEDICAL ALLIED SERVICES LIMITED

TORAL BHADRA
COMPANY SECRETARY AND COMPLIANCE OFFICER

MEMBERSHIP NO.: A56927 DATE: APRIL 19, 2024

PLACE: MUMBAI



QMS Medical Allied Services Screens 2 Lakhs Patients through 25,000 Unique Service Programs

Mumbai 19th April 2024 – QMS Medical Allied Services Limited (NSE Code: QMSMEDI), engaged in the marketing and distribution of a wide range of medical products, as well as prioritizing Patient Services Programs, has achieved a significant milestone in healthcare provision of conducting over 25,000 unique patient service programs during the fiscal year 2023-24.

These programs, conducted in collaboration with leading pharmaceutical companies nationwide, have enabled advanced diagnostic screening tests, including Diabetic Retinopathy Testing, Spirometry testing, and Bone Mineral Density testing, for 2 Lakh patients across the country.

In addition to diagnostic services, QMS MAS has played a pivotal role in addressing lifestyle management disorders through their vast network of nutritionists. These professionals have conducted a large number of dietary consultations, providing personalized guidance to individuals suffering from lifestyle diseases such as diabetes and high blood pressure.

This achievement highlights QMS MAS's dedication to improving healthcare access and fostering holistic well-being nationwide. As one of the prominent healthcare providers, QMS MAS reaffirms its commitment to proactive patient care and community health enhancement.

Commenting on the unique patient service programs, **Mr. Mahesh Makhija**, **Chairman and Managing Director of QMS Medical Allied Services Limited, mentioned,** "It is our pleasure to announce that QMS Medical Allied Services has successfully screened 2 lakhs patients through 25,000 unique service programs.

We project a growth of over 45% in our patient service programs this year due to increasing demand. Besides the potential revenue and profitability boost, this expansion will ensure broader accessibility to crucial screening measures. This aligns with our commitment to advocating preventive healthcare and ultimately contributing to the well-being of more individuals nationwide."

About QMS Medical Allied Services Limited

Incorporated in 2017, QMS Medical Allied Services Limited is a leading medical and healthcare entity in India, specializing in the marketing and distribution of essential devices and accessories. With a focus on quality and affordability, the company offers a wide range of devices through it's partnership with brands like 3M & Heine, & also it's own "Q-Devices" brand. These products include glucometers, pulse oximeters, orthopaedic aids, mesh nebulizers and many more. Its extensive distribution network ensures broad accessibility, while strategic marketing efforts bolster brand recognition and expansion.

QMS MAS emerges as a prominent healthcare services provider in India, deeply committed to advancing preventive healthcare. A significant aspect is its second vertical, offering Patient Service Programs to the public. These programs provide consumers unprecedented access to specialized screening tests across the country. They serve as a driver to of preventative healthcare amongst all Indians and will eventually drive down the healthcare costs arising due to chronic disease medication and hospitalization.

In FY23, the Company has reported Total Revenue of ₹ 104.04Cr with EBITDA of ₹ 12.07Cr & Net Profit of ₹ 6.38Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private LimitedSunil Mudgal – Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com